<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979341</url>
  </required_header>
  <id_info>
    <org_study_id>AntalyaIVF-RCT-dual trigger</org_study_id>
    <secondary_id>App. No. 01042013/103</secondary_id>
    <nct_id>NCT01979341</nct_id>
  </id_info>
  <brief_title>The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes</brief_title>
  <official_title>Dual Trigger With Gonadotropin-releasing Hormone Agonist (GnRHa) and Human Chorionic Gonadotropin (hCG) to Optimize ICSI Reproductive Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antalya IVF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antalya IVF</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of antagonist controlled ovarian stimulation protocols has allowed the use of GnRH
      agonist to be used for final oocyte maturation. The use of GnRH agonist as ovulation trigger
      has been shown to reduce the risks for ovarian hyperstimulation syndrome (OHSS), but its
      sole use results in reduced embryo implantation due to luteal phase insufficiency. The
      combination of GnRH agonist and variable doses of hCG for final oocyte maturation has been
      shown to overcome the luteal phase insufficiency effecting endometrial receptivity.

      In this study the investigators will test the hypothesis that using GnRH agonist (0.2mg
      Triptorelin) and a full dose of hCG (6500IU Ovitrelle) for final oocyte maturation in
      normoresponders will increase oocyte maturity, embryo quality and embryo implantation and
      reduce ovarian hyperstimulation syndrome, as compared to the traditional hCG (full dose)
      alone trigger.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    treatment strategy changed
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>embryo implantation rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of fetal sacs per embryo transferred to a patient's uterus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oocyte maturation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the percentage of oocytes that are at the metaphase II (nuclear mature) stage at the time of oocyte collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian hyperstimulation syndrome</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>a complication arising from ovarian hyperstimulation with the use of exogenous hormones and ovulation induction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of patients with an ultrasound confirmed fetal heart 7 weeks after the transfer of embryos to patient uteruses</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pregnancy</condition>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>Dual trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>final oocyte maturation trigger</intervention_name>
    <description>when â‰¥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only</description>
    <arm_group_label>Dual trigger</arm_group_label>
    <arm_group_label>hCG trigger</arm_group_label>
    <other_name>dual trigger: 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)</other_name>
    <other_name>hCG trigger: 6500 IU Ovitrelle (hCG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age; &lt; 40 years

          -  Cycle number; cycles 1 or 2

          -  Antral follicle count; &gt;10 and &lt;25

          -  BMI; &gt;18 and &lt;30

          -  Normogonadotrophic cycle length; 24 to 25 days

          -  Male; ejaculated semen only

        Exclusion Criteria:

          -  Presence of endocrine disorders; (diabetes mellitus, hyperprolactinemia, thyroid
             dysfunction, congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary
             syndrome)

          -  Previous major uterine surgery (that would affect endometrial receptivity)

        Secondary exclusion criteria

          -  &lt;5 follicles at the time of trigger

          -  &lt;2 full formed blastocyst on day 5 of embryo culture
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Bulut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya IVF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kemal Ozgur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya IVF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antalya IVF</name>
      <address>
        <city>Antalya</city>
        <zip>07080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 22, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Antalya IVF</investigator_affiliation>
    <investigator_full_name>Kevin Coetzee</investigator_full_name>
    <investigator_title>Scientific Advisor</investigator_title>
  </responsible_party>
  <keyword>dual trigger</keyword>
  <keyword>hCG</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>ICSI</keyword>
  <keyword>pregnancy</keyword>
  <keyword>OHSS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Triptorelin</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
